Phase II trial Combining Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer

Dr. Yang-Min Ning and collaborators reported, in the April 20, 2010 issue of the Journal of Clinical Oncology, a Phase II trial which combined chemotherapy (docetaxel) with an anti-angiogenesis drug for men with castration-resistant prostate cancer (CRPC). The data suggests that such a combination is more effective than chemotherapy alone. […]

A Phase II Trial, A New Type Of Vaccine For Prostate Cancer

I have to admit that cancer researchers are becoming very creative. There is a phase II clinical trial getting ready to start at the Wake Forest University Baptist Medical Center which has a new twist. The treatment is based on injecting white blood cells called 'cancer killing' granulocytes from healthy donors into cancer survivors with [...]

By |2008-08-11T08:55:20-04:00